Supplementary Digital Content

Table 1:Updated and original tests: Percentage of subjects with hSBA-MenCtiters≥ 1:4 and ≥1:8 and GMTs (ATP cohort for persistence Year 1, subset of subjects retested with updated hSBA-MenC test)

|  | | | | | | | **≥ 1:4** | | | | | | **≥ 1:8** | | | | | | | | **GMT** | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | |  | | | **95% CI** | | |  | | | | **95% CI** | | | |  | | **95% CI** | | | |
| **Antibody** | **Group** | | **Timing** | | **N** | | **n** | | **%** | **LL** | **UL** | | **n** | | **%** | | **LL** | | **UL** | | **value** | | **LL** | | **UL** | |
| **Updated test** | | |  | |  | |  | |  |  |  | |  | |  | |  | |  | |  | |  | |  | |
| hSBA-MenC | HibMenCY x 4 | | Year 1 | | 23 | | 23 | | 100 | 85.2 | 100 | | 23 | | 100 | | 85.2 | | 100 | | 186.4 | | 106.5 | | 326.2 | |
| (updated) | Hib | | Year 1 | | 9 | | 2 | | 22.2 | 2.8 | 60.0 | | 1 | | 11.1 | | 0.3 | | 48.2 | | 2.9 | | 1.6 | | 5.3 | |
|  | HibMenCY x 1 | | Year 1 | | 10 | | 6 | | 60.0 | 26.2 | 87.8 | | 6 | | 60.0 | | 26.2 | | 87.8 | | 13.6 | | 3.4 | | 54.6 | |
| **Original test** | | | |  | |  | |  |  |  |  |  | |  | |  | |  | |  | |  | |  | |
| hSBA-MenC | | HibMenCY x 4 | | Year 1 | | 23 | | 23 | 100 | 85.2 | 100 | 23 | | 100 | | 85.2 | | 100 | | 247.7 | | 155.5 | | 394.5 | |
| (original) | | Hib | | Year 1 | | 9 | | 3 | 33.3 | 7.5 | 70.1 | 3 | | 33.3 | | 7.5 | | 70.1 | | 5.5 | | 1.7 | | 17.5 | |
|  | | HibMenCY x 1 | | Year 1 | | 10 | | 7 | 70.0 | 34.8 | 93.3 | 7 | | 70.0 | | 34.8 | | 93.3 | | 27.4 | | 6.6 | | 114.0 | |

GMT = geometric mean antibody titre calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titre equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Year 1 = 309-421 days post- dose 4 blood sample